Certara, Inc. $CERT Stock Position Cut by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its stake in Certara, Inc. (NASDAQ:CERT) by 21.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 174,787 shares of the company’s stock after selling 46,763 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Certara were worth $2,045,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AdvisorNet Financial Inc bought a new position in Certara in the 2nd quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new position in Certara in the 1st quarter valued at about $31,000. AlphaQuest LLC acquired a new stake in Certara in the 1st quarter valued at about $39,000. Quarry LP acquired a new stake in Certara in the 1st quarter valued at about $98,000. Finally, Associated Banc Corp acquired a new stake in Certara in the 1st quarter valued at about $101,000. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $11.58 on Thursday. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a one year low of $8.64 and a one year high of $15.69. The firm has a market capitalization of $1.86 billion, a PE ratio of 231.65 and a beta of 1.45. The firm has a 50-day moving average of $11.75 and a two-hundred day moving average of $11.64.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.57 million for the quarter, compared to analysts’ expectations of $104.14 million. During the same period in the prior year, the company posted $0.07 earnings per share. Certara’s quarterly revenue was up 12.1% compared to the same quarter last year. On average, analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CERT shares. Morgan Stanley started coverage on shares of Certara in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 price target for the company. KeyCorp upped their price target on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th. Craig Hallum started coverage on shares of Certara in a report on Monday, September 29th. They issued a “buy” rating and a $16.00 price target for the company. Barclays upped their price target on shares of Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Certara currently has an average rating of “Hold” and an average price target of $15.63.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.33% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.